# LDL Particle Concentration as a Causal Driver of Atherosclerotic Cardiovascular Disease: research update

Dated 5 October 2026. Local prepublication addendum; archived grade unchanged.

Human genetics, multiple drug classes and experimental retention evidence support a causal role for atherogenic lipoprotein exposure. Remaining gaps concern the best exposure metric, lifetime treatment timing and populations in which lowering does not reduce the measured outcome.

## Research timeline

Electronic year is used where recorded; issue year is retained in each source card. The chronology is selected, not exhaustive, and does not establish priority or causation.

| Year | Primary study | Design and finding | Inference limit |
|---|---|---|---|
| 1994 | [Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S).](https://pubmed.ncbi.nlm.nih.gov/7968073/) | 4S randomized statin trial. Simvastatin reduced coronary events and improved survival in established coronary disease. | A drug effect is not an isolated manipulation of particle count versus cholesterol content. |
| 2002 | [Subendothelial retention of atherogenic lipoproteins in early atherosclerosis.](https://pubmed.ncbi.nlm.nih.gov/12066187/) | Proteoglycan-binding-defective LDL mouse experiment. Reduced arterial retention affinity lowered atherosclerosis. | A model mechanism does not quantify every human risk pathway. |
| 2005 | [Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis.](https://pubmed.ncbi.nlm.nih.gov/16034009/) | 4D randomized dialysis trial. Atorvastatin did not significantly improve the composite primary endpoint. | Advanced renal disease and competing pathology bound broad extrapolation. |
| 2006 | [Sequence variations in PCSK9, low LDL, and protection against coronary heart disease.](https://pubmed.ncbi.nlm.nih.gov/16554528/) | PCSK9 genetic cohort. Lifelong genetically lower LDL was associated with fewer coronary events. | Genetic exposure timing and possible pleiotropy differ from starting treatment later. |
| 2015 | [Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.](https://pubmed.ncbi.nlm.nih.gov/26039521/) | IMPROVE-IT randomized trial. Adding ezetimibe lowered LDL further and improved cardiovascular outcomes. | The achieved exposure changes multiple correlated lipid measures. |
| 2017 | [Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.](https://pubmed.ncbi.nlm.nih.gov/28304224/) | FOURIER randomized trial. PCSK9 inhibition lowered LDL and reduced cardiovascular events. | Background therapy, population risk and follow-up duration define scope. |
| 2020 | [Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis.](https://pubmed.ncbi.nlm.nih.gov/32203549/) | Multivariable Mendelian randomization. ApoB accounted for much of the modeled lipid–coronary relationship. | Correlated traits and conditional instrument strength limit exclusive component attribution. |
| 2023 | [Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients.](https://pubmed.ncbi.nlm.nih.gov/36876740/) | CLEAR Outcomes randomized trial. Bempedoic acid reduced major events in statin-intolerant patients. | Benefits and adverse effects remain population- and drug-specific. |
| 2025 | [Evolocumab in Patients without a Previous Myocardial Infarction or Stroke.](https://pubmed.ncbi.nlm.nih.gov/41211925/) | VESALIUS-CV randomized trial. Evolocumab reduced first events in high-risk people without previous myocardial infarction or stroke. | Atherosclerosis or diabetes eligibility is not unrestricted low-risk primary prevention. |

## Research gaps

### G1: When does LDL cholesterol cease to represent the causal exposure adequately?

Evidence anchors: [P32203549](https://pubmed.ncbi.nlm.nih.gov/32203549/), [P16554528](https://pubmed.ncbi.nlm.nih.gov/16554528/), [P26039521](https://pubmed.ncbi.nlm.nih.gov/26039521/), [P28304224](https://pubmed.ncbi.nlm.nih.gov/28304224/).

Competing explanation: Particle number, particle type and cholesterol content may diverge while conventional LDL-C remains correlated.

Discriminating test and controls: Prospective discordance analyses and orthogonal instruments with conditional-strength checks; measure apoB, LDL-C, remnants and lipoprotein(a).

### G2: Why do advanced dialysis populations differ?

Evidence anchors: [P16034009](https://pubmed.ncbi.nlm.nih.gov/16034009/), [P7968073](https://pubmed.ncbi.nlm.nih.gov/7968073/), [P28304224](https://pubmed.ncbi.nlm.nih.gov/28304224/).

Competing explanation: Competing nonatherosclerotic events or irreversible disease may dominate outcomes.

Discriminating test and controls: Mechanism-specific outcome adjudication and disease-stage studies with competing-risk analyses; distinguish null benefit in a population from absence of causal atherogenesis.

### G3: How much benefit comes from earlier and longer exposure reduction?

Evidence anchors: [P16554528](https://pubmed.ncbi.nlm.nih.gov/16554528/), [P41211925](https://pubmed.ncbi.nlm.nih.gov/41211925/), [P36876740](https://pubmed.ncbi.nlm.nih.gov/36876740/).

Competing explanation: Short clinical trials underestimate cumulative lifelong exposure effects and can miss later harms.

Discriminating test and controls: Extended follow-up and earlier-treatment randomized evidence where feasible, with absolute-risk and adherence measures; do not equate genetic and drug effect sizes.

### G4: Which residual risks are not mediated by LDL lowering?

Evidence anchors: [P12066187](https://pubmed.ncbi.nlm.nih.gov/12066187/), [P32203549](https://pubmed.ncbi.nlm.nih.gov/32203549/), [P28304224](https://pubmed.ncbi.nlm.nih.gov/28304224/).

Competing explanation: Inflammation, other apoB particles, thrombosis and established plaque can contribute independently.

Discriminating test and controls: Factorial or complementary interventions with prespecified lipid and nonlipid pathways, hard events and target engagement.

## Methods and access

Case-specific Consensus records assisted gap discovery, chronology and targeted paper questions. Shared template wording about an amyloid-specific Deep follow-up is not evidence of a Deep run for this topic; the dated source records establish the actual use and access limits. Primary identifiers, selected abstract passages, correction notices and available primary-body passages were cross-checked. Generated absence cells, duplicate milestones and unsupported access claims were rejected.

This focused addendum does not establish 50–70 complete primary Methods/Results examinations per review. Baseline reading receipts and scores retain their original scope.

Checked timeline sources: 9; selected full-text checks: 1; abstract-excerpt checks: 8; metadata-only historical anchors: 0. Complete papers examined in this update: 0.

Historical scorecards declare schema 5.4. This enrichment uses HSEF v5.3 causal distinctions without retrospectively relabelling or rescoring those files.

Targeted paper-check scope: Methods table and instrument-strength paragraph: conditional apoB F-statistics of 36 and 66 are present in the primary text, although unavailable in Consensus excerpts. These do not imply every correlated exposure is independently identified.

Editorial correction/limit: VESALIUS-CV has a 2026 issue date and a 2025 electronic publication date. Its high-risk first-event population is narrower than a claim about all primary prevention.